Scoring system study for advanced pancreatic cancer
Part of Cancer clinical trials.
This study looks at a scoring system to predict how well people with advanced pancreatic cancer might do after their first chemotherapy. If you have been diagnosed with this type of cancer and are about to start or have just finished your first treatment, this study may be able to use your health information to help guide future care.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a confirmed diagnosis of pancreatic ductal adenocarcinoma (a common type of pancreatic cancer)
- You are 18 years or older
- You have not had any other cancer treatment except your first chemotherapy for this cancer
- You have had blood tests (like complete blood count, liver and kidney function, and tumor markers) before starting your first treatment
- You have at least one tumor that can be measured on a scan
- Your daily activity level is good (ECOG score 0 or 1)
- You are expected to live at least 3 more months
- You are not pregnant or breastfeeding
- You agree to join the study and sign a consent form
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at blood and stool samples from people with advanced pancreatic cancer to understand how their body's metabolism and gut bacteria affect their disease and treatment. It aims to find better ways to predict and improve treatment outcomes.
This Phase 2 trial is for people with pancreatic ductal adenocarcinoma (a type of pancreatic cancer) confirmed by biopsy. It tests a new treatment strategy after the cancer is diagnosed and considers people who haven’t had certain chemotherapy yet.
This study checks if a simple blood test can find tiny bits of cancer DNA after your pancreatic surgery, which may help detect if cancer comes back earlier than scans. By joining, you'll help doctors learn how to better monitor the disease and guide future treatments.
This study uses a special blood test to look for tiny amounts of cancer DNA after your pancreatic cancer surgery. It may help doctors see early if the cancer is coming back, so they can act sooner.
This registry collects information about people with advanced pancreatic cancer who are receiving first-line palliative treatment. It helps doctors understand which treatment choices are used and how people do over time.
This study looks at advanced or metastatic pancreatic cancer patients and uses stored tumor tissue to learn what may predict treatment outcomes. You may be able to join if you have had limited prior chemotherapy and can provide an archived tissue sample.
Hear when a new Pancreatic Ductal Adenocarcinoma (PDAC) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.